592
Participants
Start Date
June 1, 2018
Primary Completion Date
April 11, 2024
Study Completion Date
April 11, 2024
Market Approved RF Ablation System
Subjects receive ablation using an FDA approved radiofrequency (RF) ablation system.
FlexAbility SE Ablation Catheter
Subjects receive ablation treatment using an ablation system that is not FDA approved.
Royal Adelaide Hospital, Adelaide
IKEM, Prague
Nemocnice Na Homolce, Prague
Hospital of the University of Pennsylvania, Philadelphia
Ospedale San Raffaele, Milan
Centro Cardiologico Monzino, Milan
Johns Hopkins University Hospital, Baltimore
WakeMed Hospital, Raleigh
Medical University of South Carolina, Charleston
Emory University Hospital, Atlanta
Memorial Regional Hospital, Hollywood
Broward General Medical Center, Fort Lauderdale
Hopital Haut Leveque, Pessac
University of South Florida, Tampa
Affinity Cardiovascular Specialists, LLC, Birmingham
University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham
Vanderbilt Heart and Vascular Institute, Nashville
University of Michigan, Ann Arbor
VA Medical Center Minneapolis, Minneapolis
Mayo Clinic, Rochester
University of Chicago, Chicago
Texas Heart Institute, Houston
Memorial Hermann Hospital, The Woodlands
Texas Cardiac Arrhythmia, Austin
University of Colorado Hospital, Aurora
USC University Hospital, Los Angeles
Ronald Reagan UCLA Medical Center, Los Angeles
University of California at San Diego (UCSD) Medical Center, San Diego
University of Washington, Seattle
Herzzentrum Leipzig GmbH, Leipzig
Hospital General Universitario Gregorio Marañón, Madrid
St. Georges Hospital, London
Lead Sponsor
Abbott Medical Devices
INDUSTRY